Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 6/20 | 0.45 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.44 |
| ▸ | HTR3B | O95264 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.44 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.44 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2191827 | 0.78 | CRHR1 (0.57) | CRHR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5045653 | 0.76 | BCL2A1 (0.40) | CRHR1SRD5A1KDM4EHTTKMT2A | |
| SCHEMBL5043609 | 0.73 | GAA (0.35) | KDM4EPKMSMN1; SMN2TP53HSD17B10 | |
| SCHEMBL2192949 | 0.72 | KDM4E (0.72) | CRHR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2193106 | 0.72 | HTR3E (0.45) | CRHR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5044811 | 0.72 | OPRM1 (0.32) | HSD17B10 | |
| SCHEMBL23121035 | 0.70 | DDB1 (0.60) | CRHR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL29607852 | 0.70 | DDB1 (0.60) | CRHR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5045550 | 0.70 | CRHR1 (0.52) | CRHR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5039157 | 0.69 | ALOX5 (0.42) | ALDH1A1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432283-B2 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC (US) | 2008-10-07 | — | — | US | disclosed |
| US-7268146-B2 | Ring fused pyrazole derivatives as CRF antagonists | PALO ALTO LLC (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1453832-B1 | RING FUSED PYRAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-08-09 | — | — | EP | disclosed |
| US-20060135555-A1 | (3,4-Dihydro-1H-isoquinolin-2-yl)-[2-methyl-7-(2,4,6-trimethyl-phenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-b]pyridin-3-yl]-methanone; Corticotropin releasing factor (CRF); stress-related illnesses, mood disorders such as depression, major depressive disorder, single episode depression | ROCHE PALO ALTO LLC | 2006-06-22 | — | — | US | disclosed |
| US-7053103-B2 | Ring fused pyrazole derivatives as CRF antagonists | SYNTEX (U.S.A.) LLC (US) | 2006-05-30 | — | — | US | disclosed |
| US-20050197330-A1 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC | 2005-09-08 | — | — | US | disclosed |
| US-20050014781-A1 | Ring fused pyrazole derivatives as CRF antagonists | LOUGHHEAD DAVID GARRETT (US) | 2005-01-20 | — | — | US | disclosed |
| US-6821984-B2 | FOR THERAPY OF PSYCHIATRIC DISORDERS AND NEUROLOGICAL DISEASES | SYNTEX (U.S.A.) LLC | 2004-11-23 | — | — | US | disclosed |
| EP-1453832-A1 | RING FUSED PYRAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2004-09-08 | — | — | EP | disclosed |
| US-20040006066-A1 | Ring fused pyrazole derivatives as CRF antagonists | SYNTEX (U.S.A.) LLC | 2004-01-08 | — | — | US | disclosed |
| WO-2003048160-A1 | RING FUSED PYRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135555-A1 | (3,4-Dihydro-1H-isoquinolin-2-yl)-[2-methyl-7-(2,4,6-trimethyl-phenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-b]pyridin-3-yl]-methanone; Corticotropin releasing factor (CRF); stress-related illnesses, mood disorders such as depression, major depressive disorder, single episode depression | CRHR1, CRH, CRHR2 | CRHR1 1/4885HTR3E 39/4885HTR3B 11/4885 |
| US-20050197330-A1 | Heterocyclic GABAA subtype selective receptor modulators | GABRA2, GABRA1, GABRA5 | CRHR1 71/4885HTR3E 90/4885HTR3B 39/4885 |
| US-20050014781-A1 | Ring fused pyrazole derivatives as CRF antagonists | CRHR1, CRHR2, MC2R | CRHR1 1/4885HTR3E 120/4885HTR3B 48/4885 |
| US-20040006066-A1 | Ring fused pyrazole derivatives as CRF antagonists | CRHR1, CRHR2, MC2R | CRHR1 1/4885HTR3E 117/4885HTR3B 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.